VEGF, particularly elevated in TNBC, not only promotes tumor progression but also serves as a key target in anti-angiogenic therapies, improving survival rates when combined with chemotherapy, as demonstrated in metastatic colorectal cancer (153). Here, VEGFA is linked to neoplasm.